CRISPR Therapeutics AG CRSP
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- -4.65%
- 1 year
- -21.86%
- Open
- 51.90
- Prev close
- 51.42
- Mkt cap
- 4.83B
- Vol
- 470.10K
- Avg vol
- 1.53M
- EPS
- -4.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 49.85
- High
- 52.12
- Forward P/E
- -14.25
- Beta
- 1.76
- Short ratio
- 9.18
- Inst. own
- 77.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 54.32
- 200-d avg
- 52.91
- 1y target
- 85.63
5D chart
Signals (124)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 1:35 PM | 51 minutes ago |
| SMA: Bearish | Nov 2, 1:05 PM | 1 hour ago |
| MACD: Buy Signal | Nov 2, 1:00 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 12:55 PM | 1 hour ago |
| MACD: Sell Signal | Nov 2, 12:25 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:05 PM | 2 hours ago |
| MACD: Buy Signal | Nov 2, 11:40 AM | 2 hours ago |
| SMA: Bearish | Nov 2, 10:35 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 3 hours ago |
| MACD: Sell Signal | Nov 2, 10:30 AM | 3 hours ago |
| SMA: Bullish | Nov 2, 10:25 AM | 4 hours ago |
| MACD: Buy Signal | Nov 2, 10:25 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 10:20 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:15 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:15 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:50 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:45 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 4 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 4 hours ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:55 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| RSI: Overbought | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| RSI: Overbought | Oct 27, 12:20 PM | 6 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 6 days ago |
News
3 hours ago zacks.com
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 hours ago globenewswire.com
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer,…
2 days ago zacks.com
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
3 days ago zacks.com
3 Promising Genomics Stocks to Add to Your Portfolio Now
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
1 week ago fool.com
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other…
1 week ago zacks.com
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
1 week ago zacks.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
1 week ago zacks.com
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
-
1 week ago benzinga.com
CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad
CRISPR Therapeutics (NASDAQ:CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the…
1 week ago globenewswire.com
CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the…
2 weeks ago fool.com
Where Will CRISPR Therapeutics Stock Be in 2030?
CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory…
2 weeks ago fool.com
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.
2 weeks ago zacks.com
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
-
2 weeks ago benzinga.com
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52
UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.
2 weeks ago zacks.com
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.
3 weeks ago zacks.com
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 weeks ago fool.com
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Substantial revenue from its flagship drug Casgevy should be right around the corner. Investors can expect a pivotal update on CTX310 before the end of the year.
3 weeks ago globenewswire.com
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational…
3 weeks ago zacks.com
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.
3 weeks ago schaeffersresearch.com
3 Trending Names Overtaking Wall Street Today
Crisper Therapeutics (CSPR), Arista Networks (ANET), and Nebius (NBIS) are all seeing outsized intraday moves today
3 weeks ago benzinga.com
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
4 weeks ago zacks.com
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)…
1 month ago globenewswire.com
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its…
1 month ago zacks.com
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
1 month ago benzinga.com
Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets
Cathie Wood explains why Tesla, Coinbase, and CRISPR lead her "Rapid Real Growth" thesis as 5 tech platforms transform global GDP.
2 months ago benzinga.com
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
-
2 months ago benzinga.com
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
-
2 months ago benzinga.com
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3.…
-
2 months ago benzinga.com
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
2 months ago benzinga.com
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
2 months ago benzinga.com
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
2 months ago benzinga.com
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
-
3 months ago benzinga.com
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.
-
3 months ago benzinga.com
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
-
3 months ago benzinga.com
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
4 months ago benzinga.com
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in…
4 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
4 months ago benzinga.com
Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far
Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the technology-heavy Nasdaq 100 Index.
-
5 months ago benzinga.com
Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56
Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.
-
5 months ago benzinga.com
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $80 to $82.
-
7 months ago benzinga.com
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $105 to $110.
7 months ago benzinga.com
What's Going On With CRISPR Therapeutics Stock Today?
CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshadowing recent momentum from Casgevy uptake and fourth-quarter revenue growth.
-
7 months ago benzinga.com
Reported Earlier: CRISPR Therapeutics Plans $350M Convertible Note Offering, Maturing 2031, To Fund Corporate Purposes
- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its…
7 months ago benzinga.com
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving lower in pre-market trading.
7 months ago benzinga.com
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
8 months ago benzinga.com
Why Is CRISPR Therapeutics Stock Surging Thursday?
CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.
9 months ago benzinga.com
Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch
Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should watch.
9 months ago benzinga.com
Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning?
Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challenging users to interpret a series of custom images called "ARKmoji" to understand their picks for the year.
9 months ago benzinga.com
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing in 2026 as competition in blood disorders intensifies.